Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - metronidazole, quantity: 500 mg - injection, solution - excipient ingredients: citric acid monohydrate; water for injections; sodium chloride; dibasic sodium phosphate dodecahydrate - metronidazole intravenous infusion is indicated:,(a) for treatment of anaerobic infections in patients for whom oral administration is not possible.,(b) where immediate anti-anaerobic chemotherapy is required.,(c) where prophylactic cover is required at lower abdominal surgical sites presumed contaminated or potentially contaminated by anaerobic micro-organisms. procedures of this type include appendectomy, colonic surgery, vaginal hysterectomy, abdominal surgery in the presence of anaerobes in the peritoneal cavity and surgery performed in the presence of anaerobic septicaemia.,note: metronidazole is inactive against aerobic or facultative anaerobic bacteria.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - amidotrizoate meglumine, quantity: 660 mg/ml; sodium amidotrizoate, quantity: 100 mg/ml - injection, solution - excipient ingredients: sodium calcium edetate; water for injections - intravenous and retrograde urography. computerized tomography. also for all angiographic examinations as well as for aminography, arthrography, intraoperative cholangiography, fistulography, hysterosalpingography, splenoportography, vesiculography and others. urografin is not to be used for myelography, ventriculography of cisternography, since it is likely to provoke neurotoxic symptoms in these examinations.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - iopromide, quantity: 623.4 mg/ml - injection - excipient ingredients: trometamol; dilute hydrochloric acid; water for injections; sodium calcium edetate; sodium hydroxide - all angiographic and urographic examinations and for contrast enhancement in computerised tomography.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - iopromide, quantity: 311.7 mg/ml - injection - excipient ingredients: trometamol; water for injections; sodium calcium edetate; dilute hydrochloric acid; sodium hydroxide - all angiographic and urographic examinations and for contrast enhancement in computerised tomography.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - iopromide, quantity: 768.86 mg/ml - injection, solution - excipient ingredients: water for injections; dilute hydrochloric acid; trometamol; sodium calcium edetate; sodium hydroxide - all angiographic and urographic examinations and for contrast enhancement in computerised tomography.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - iopromide, quantity: 768.86 mg/ml - injection, solution - excipient ingredients: trometamol; dilute hydrochloric acid; water for injections; sodium calcium edetate; sodium hydroxide - all angiographic and urographic examinations and for contrast enhancement in computerised tomography.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - iopromide, quantity: 768.86 mg/ml - injection, solution - excipient ingredients: dilute hydrochloric acid; sodium calcium edetate; trometamol; water for injections; sodium hydroxide - ultravist is indicated for all angiographic and urographic examinations and for contrast enhancement in computerised tomography.,ultravist 300 or 370 is indicated for use in contrast-enhanced mammography (cem) in adults, to visualise known or suspected lesions of the breast as an adjunct to mammography (with or without ultrasound).

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - dexmedetomidine hydrochloride, quantity: 4.72 microgram/ml (equivalent: dexmedetomidine, qty 4 microgram/ml) - injection, intravenous infusion - excipient ingredients: sodium chloride; water for injections - intensive care unit (icu) sedation: for sedation of initially intubated adult patients during treatment in an intensive care setting. the use of precedex ready to use by continuous infusion in these patients should not exceed 24 hours.,procedural sedation: for sedation of non-intubated adult patients prior to and/or during surgical and other procedures.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - dexmedetomidine hydrochloride, quantity: 4.72 microgram/ml (equivalent: dexmedetomidine, qty 4 microgram/ml) - injection, intravenous infusion - excipient ingredients: sodium chloride; water for injections - intensive care unit (icu) sedation: for sedation of initially intubated adult patients during treatment in an intensive care setting. the use of precedex ready to use by continuous infusion in these patients should not exceed 24 hours.,procedural sedation: for sedation of non-intubated adult patients prior to and/or during surgical and other procedures.

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - topiramate 100mg;   - film coated tablet - 100 mg - active: topiramate 100mg   excipient: colloidal silicon dioxide croscarmellose sodium opadry yellow 85g32313 magnesium stearate mannitol microcrystalline cellulose pregelatinised maize starch - topiramate actavis is indicated in adults and children. topiramate actavis tablet range is not suitable for any children weighing less than 25 kg and is not suitable as monotherapy for children or adolescents weighing less than 50 kg. - as monotherapy in patients with newly diagnosed epilepsy - for conversion to monotherapy in patients with epilepsy - as add-on therapy in partial onset seizures, generalised tonic-clonic seizures or seizures associated with lennox-gastaut syndrome.